Eikon Therapeutics, Inc.
EIKN$529M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMILLBRAE
Drugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Jun 29, 2026
12dMarket Overview
Stock performance and key metrics
EIKN News
Catalyst Timeline
4 upcoming, 0 past
EarningsNext
EIKN Earnings Report
Jun 29, 2026Confirmed
EPS Est: $-1.47 | FQ end 2026-03
3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
EIK1001
Advanced Melanoma
Paclitaxel + Carboplatin
Non Small Cell Lung Cancer (Squamous or Non Squamous)
EIK1005
Advanced Solid Tumors
EIK1004-001 (IMP1707-001)
Advanced Solid Tumors
Paclitaxel
NSCLC
BDB001
Tumor, Solid
IMP1734
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EIK1001 | Phase 3 | Advanced Melanoma | - | - |
Paclitaxel + Carboplatin | Phase 3 | Non Small Cell Lung Cancer (Squamous or Non Squamous) | - | - |
EIK1005 | Phase 2 | Advanced Solid Tumors | - | - |
EIK1004-001 (IMP1707-001) | Phase 2 | Advanced Solid Tumors | - | - |
Paclitaxel | Phase 2 | NSCLC | - | - |
BDB001 | Phase 2 | Tumor, Solid | - | - |
IMP1734 | Phase 2 | Advanced Solid Tumor | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply